Ianalumab Prolongs Time to Treatment Failure in Primary ITP
Adding ianalumab to standard-of-care second-line eltrombopag prolonged the time to treatment failure vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) in …
Multiple AD Tx Options Leading to Individualized Therapy
Dec 18, 2025 · Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.
Anti-inflammatory Targets for HS Likely Vary by Patient
Dec 30, 2025 · The progress in understanding the pathophysiology of hidradenitis suppurativa appears to be leading to treatment strategies individualized for disease phenotype.
RSV Raises Risk for Diverse Complications Across Adulthood
Jul 11, 2025 · Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond pulmonology, including poor kidney outcomes and …
Inflammation Now the Key Target for Seborrheic Dermatitis
Jan 6, 2025 · The underlying pathophysiology of seborrheic dermatitis was once unclear, but there is now overwhelming evidence that inflammation is the driving force.
ASH 2025 - Medscape
Dec 17, 2025 · American Society of Hematology (ASH) 2025 Annual Meeting : Read clinically focused news coverage of key developments from ASH 2025
Why Genitourinary Syndrome of Menopause Is Often Missed
Sep 17, 2025 · Genitourinary syndrome of menopause affects sexual, genital, and urinary health, but timely care and simple steps can restore comfort and improve quality of life.
Europe Set to Approve New Immune Thrombocytopenia Therapy
Oct 17, 2025 · The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who are refractory to other treatments.
NICE Recommends Avatrombopag for Chronic Immune …
Draft final guidance published by NICE recommends avatrombopag for adults in England and Wales with primary chronic immune thrombocytopenia who are refractory to other treatments.
Targeted but Toxic? Addressing the Safety Challenges of ADCs
Jul 30, 2025 · Antibody-drug conjugates offer targeted power but come with distinct side effects. Learn how clinicians are tackling toxicity while maximizing efficacy in metastatic breast cancer.